Providers: $25.5 billion in Provider Relief Fund & American Rescue Plan rural funding is now available. Submit your application by October 26, 2021.

Allowable Expenses

RHCs funded under the RHC COVID-19 Testing and Mitigation Program and/or RHC COVID-19 Testing Program may apply any of the payments to COVID-19 testing and COVID-19 testing-related expenses.

RHCs funded under the RHC COVID-19 Testing and Mitigation Program may also apply the payments to COVID-19 mitigation and COVID-19 mitigation-related expenses.

COVID-19 Testing Expenses

COVID-19 testing described in the RHC COVID-19 Testing and Mitigation Terms and Conditions and the RHC COVID-19 Testing Program Terms and Conditions include, but are not limited to:

Viral tests to diagnose active COVID-19 infections

  • A viral test checks specimens from your nose or your mouth to find out if you are currently infected with the virus that causes COVID-19. Two types of viral tests are uses: nucleic acid amplification tests (NAATs) and antigen tests.1
  • Viral tests can also be used as screening tests to reduce transmission of SARS-CoV-2 by identifying infected (symptomatic and exposed) persons who need to isolate from others.
  • Viral tests can be performed in the following settings including, but not limited to:
    • Laboratory (complete laboratory and/or partial laboratory cycle (i.e., phases))
    • Testing site (onsite and/or off-site/third party COVID-19 testing with active RHC involvement in the administration and oversight)
    • At home or anywhere else (prescription and/or non-prescription (i.e., home collection; direct-to-consumer; over-the-counter)). 2,3

1 Centers for Disease Control. (2021).
2 U.S. Food and Drug Administration. (2021).
3 U.S. Department of Health and Human Services, Office of the Inspector General. (2021).

Antibody testing (serology) tests to diagnose past COVID-19 infections

  • Antibody or serology tests look for antibodies in your blood to determine if you had a past infection with the virus that causes COVID-19.
  • Antibody tests should not be used to diagnose a current infection with the virus that causes COVID-19, except in instances in which viral testing is delayed.
  • An antibody test may not show if you have a current infection because it can take 1-3 weeks after the infection for your body to make antibodies.4

4 Centers for Disease Control. (2021).

COVID-19 Mitigation Expenses

COVID-19 mitigation includes efforts, activities, and strategies to reduce or prevent local COVID-19 transmission and minimize morbidity and mortality of COVID-19 in places such as schools, workplaces, and healthcare organizations, described in the RHC COVID-19 Testing and Mitigation Terms and Conditions and in the CDC Community Mitigation Framework. Community mitigation efforts aim to reduce the rate at which someone infected comes in contact with someone not infected, or reduce the probability of infection if there is contact. The more a person interacts with different people, and the longer and closer the interaction, the higher the risk of COVID-19 spread. Mitigation activities may include, but are not limited to:

Case investigation

Contact tracing

Screening

Post-COVID conditions management

Health behavior promotion

Maintain healthy environments

COVID-19 Testing-Related Expenses

Related testing expenses are described in the RHC COVID-19 Testing and Mitigation Program Terms and Conditions and the RHC COVID-19 Testing Program Terms and Conditions. The RHC must demonstrate that the related expense complies with all federal cost principles and is directly and reasonably related to the provision of COVID-19 testing activities. The related expense must be appropriate given relevant clinical and public health guidance. Related expenses include, but are not limited to:

Supplies to provide testing

Personal protective equipment (PPE)

Workforce

Health care setting/facility

COVID-19 Mitigation-Related Expenses

Related COVID-19 mitigation expenses are described in the RHC COVID-19 Testing and Mitigation Program Terms and Conditions. The RHC must demonstrate that the related expense complies with all federal cost principles and is directly and reasonably related to the provision of COVID-19 testing activities and/or COVID-19 mitigation activities. The related expense must be appropriate given relevant clinical and public health guidance. Related expenses include, but are not limited to:

Workforce

Health care setting/facility

Digital technologies

Unallowable Expenses

RHC CTM Program and RHC CT Program funds may NOT be used for direct provider-to-patient vaccine administration (i.e., shot-in-arm). Direct provider-to-patient vaccine administration does NOT include associated costs and add-on services necessary to facilitate or in conjunction with the direct provider-to-patient vaccine administration.

The following HRSA programs cover the cost of vaccine administration:

Date Last Reviewed:  August 2021